Dementia Prediction and Blood Tests; Paraquat and Parkinson’s; NIH Issues CTE Stance

Alzheimer’s blood biomarkers indicated underlying pathology but added little to current 5-year dementia risk prediction models in people with subjective cognitive complaint or mild cognitive impairment. (Neurology)

About one-third of patients spontaneously rated the term “pain catastrophizing” as problematic and 12% said having the term applied to them was a negative experience. (Journal of Pain)

New data shed more light on the effects of the weedkiller paraquat on brain tissue and its link with Parkinson’s disease. (The Guardian)

Mediterranean and Paleolithic diets were linked with less fatigue in multiple sclerosis and better physical and mental quality of life in a network meta-analysis. (Neurology)

Cerebrovascular insulin receptors were defective in post-mortem Alzheimer’s brains and a mouse model of Alzheimer’s disease. (Brain)

X-linked ubiquitin specific peptidase 11 (USP11) is more abundant in women than men and may play a role in women’s higher risk of Alzheimer’s disease. (Cell)

The FDA extended its review period of the investigational drug tofersen for SOD1 amyotrophic lateral sclerosis by 3 months, Biogen said.

Brain development, not age, determines when children transition from daily napping. (PNAS)

Six months of precuneus repetitive transcranial magnetic stimulation may slow cognitive and functional decline, a phase II study of mild-to-moderate Alzheimer’s disease suggested. (Brain)

The NIH National Institute Neurological Disorders and Stroke formally acknowledged for the first time that chronic traumatic encephalopathy (CTE) is caused by repetitive traumatic brain injuries, the Concussion Legacy Foundation announced.

Exoskeleton assistive devices can be personalized quickly while walking in the real world. (Nature)